ILIAS Biologics CEO On Opening Pandora’s Box For Exosome Therapeutics
Executive Summary
Emerging Company Profile: South Korea-based ILIAS Biologics aims to establish an exosome therapeutic development pathway using its platform technology EXPLOR, which is said to enable loading large therapeutic proteins into exosomes and stably deliver encapsulated cargo proteins to target cells.
You may also be interested in...
Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Turnaround For Spectrum’s Poziotinib As Phase II Cohort 2 Meets Endpoint
Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.
Need a specific report? 1000+ reports available
Buy Reports